自乳化药物输送系统增强了Passiflora ligularis叶子提取物的抗糖尿病活性
Sandra M Echeverry1, Diana P Rey1, Ivonne H Valderrama1
1Departamento de Farmacia, Universidad Nacional de Colombia, Av. Carrera 30 # 45-03 Edif. 450, Bogotá 111321, Colombia.
Pharmaceutics
|June 27, 2025
概括
与未配制的提取物相比,在糖尿病小鼠中将Passiflora ligularis提取物配制为自我乳化药物递送系统 (PLE-SEDDS) 显著改善了其抗糖尿病,抗氧化剂和降脂作用.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 药物输送系统 药物输送系统
- 自然产品化学 自然产品化学
背景情况:
- 之前的研究表明,未配制的Passiflora ligularis叶子提取物具有抗糖尿病的潜力.
- 为了提高治疗疗效,研究将其配制成一种自我乳化药物输送系统 (SEDDS).
研究的目的:
- 为了评估Passiflora ligularis提取物增强的抗糖尿病活性,该提取物被配制为PLE-SEDDS.
- 在糖尿病小鼠模型中,比较PLE-SEDDS与非配方提取物 (PLE) 的疗效.
主要方法:
- 糖尿病小鼠被用PLE和PLE-SEDDS口服治疗了21天.
- 评估了血糖水平,口服葡萄糖耐受性测试 (OGTT),氧化应激标志物 (SOD,CAT,MDA),组织病理学和血脂质配置文件.
主要成果:
- PLE-SEDDS表现出优异的抗高血糖作用,在OGTT期间BGL的最小增加为11.5%,而PLE的增加为27.4%.
- 使用PLE-SEDDS观察到增强的抗氧化活性 (增加SOD/CAT,减少MDA) 和改善的脂质概况 (降低甘油三,胆固醇,LDL-C;增加HDL-C).
- 组织学分析显示,在PLE-SEDDS组中,胰腺小岛的保存更好.
结论:
- 与未配制的PLE相比,PLE-SEDDS表现出优越的抗高血糖,低脂和抗氧化特性.
- 这种新的配方为2型糖尿病管理提供了一个有前途的治疗策略.
关键词:
帕西弗洛拉 (Passiflora) 是一种植物.催化酶的催化剂是什么糖尿病 糖尿病患者 糖尿病患者黄类-O-糖化物-O-糖化物在低脂血症下,马隆迪阿尔化物氧化应激是一种氧化应激.超氧化物脱酶的作用更多相关视频
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
270
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
270
Glucagon-like Receptor Agonists
433
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
433
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
269
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
269
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
272
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
272
Factors Influencing Drug Absorption: Presystemic Elimination
354
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
354


